Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

Junshi Biosciences has received acceptance from China’sNational Medical Products Administration (NMPA) for toripalimab ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationKey ...

Xiaoping Wu and Jicheng Yang of Wanhuida Intellectual Property analyse an invalidation decision that addresses how dosage and administration features affect the inventiveness assessment of pharmaceuti ...

Risankizumab showed high rates of clinical remission and endoscopic response when administered as subcutaneous induction therapy for moderate to severe CD.

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

A new study published in the journal of BMC Nephrology showed that subcutaneous and intravenous epoetin showed similar ...

RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability ...

Get tips for handling anxiety around biologic infusions for Crohn’s disease, such as preparing physically, focusing on comfort, and exploring at-home treatment options.

The Citizens Life Sciences Conference 2026 March 11, 2026 10:45 AM EDTCompany ParticipantsHelen Torley - President, ...

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation ...